Please login to the form below

Not currently logged in

Novo Nordisk to limit use of animal testing

Danish pharmaceutical company to stop the use of living animals to test medicine quality

Novo Nordisk is to stop the use of living animals to test the quality of batches of medicines produced by the company.

The commitment has been more than ten years in the making since the establishment of a task force by Novo to get rid of redundant product control tests in living animals or to replace them with other methods of testing.

These alternatives include the use of animal cells to measure biological activity of a medicine in place of animal tests, a switch that requires regulatory approval.

Novo's case was helped by campaigning from such organisations as the European Federation of Pharmaceutical Industries and Associations (EFPIA), the trade body representing pharma companies across Europe.

Magda Chlebus, director of the EFPIA, said: “The regulatory authorities have to accept with confidence the data that we are generating to authorise products on the market. So we need to convince them that the data developed using these new tools provide as good results for the safety of patients.”

Mads Krogsgaard Thomsen, executive vice president and chief science officer at Novo, said the move was a “milestone” for the Danish pharma company.

He said: “We have been working for more than a decade, in close collaboration with regulatory authorities around the world, to eliminate obsolete tests or develop and certify new laboratory assays that can be used instead of animals to evaluate the consistent quality of our marketed products.”

The number of animals used by Novo for such product tests has been reduced over the past few years. In the 1990s, more than 13,000 animals a year were subjected to tests, but this was reduced to 772 animals a year by 2010. The final tests to be done to confirm the quality of a batch produced Novo product were for a virus treatment, performed on November 28, 2011.

However, Novo will still use animals in its research and last year used over 60,000 living animal test subjects. The company said these are “essential for all pharmaceutical companies in the processes of discovery and development of new pharmaceuticals” with authorities demanding drug candidates are tested in living animals before they can be tested in humans.

Novo produced the video below to explain the decision.

1st December 2011

From: Regulatory



Featured jobs

Subscribe to our email news alerts


Add my company
Say Communications

Influencing positive behaviours and delivering change is what drives us, using thought leadership, education, social and professional engagement and compelling,...

Latest intelligence

World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...
World Diabetes Day: Interaction and impact of diabetes on mental health
For World Diabetes Day on the 14th November 2018, Nisha Shahrukh - Medical Writer at Mednet Group has written an article depicting the impact diabetes has on mental health. Including...
Innovation in merger control and the impact on the pharmaceutical sector
Is focusing on pipeline products enough to assess regulatory risks?...